BOSTON SCIENTIFIC CORPORATION BSX Cash Flow

Boston scientific corporation (BSX)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10	Dec'09	Sep'09	Jun'09	Mar'09
Increase (decrease) in operating assets and liabilities, net of acquisitions:
Cash provided by (used for) operating activities
-77,000	692,000	502,000	292,000	350,000	19,000	501,000	-403,000	193,000	684,000	452,000	297,000	-7,000	676,000	-31,000	421,000	116,000	420,000	408,000	60,000	-197,000	440,000	346,000	285,000	198,000	275,000	251,000	397,000	187,000	389,000	272,000	407,000	212,000	349,000	366,000	390,000	-97,000	449,000	-126,000	286,000	-284,000	-329,000	484,000	419,000	261,000
Investing activities:
Purchases of property, plant and equipment
100,000	186,000	121,000	91,000	63,000	106,000	76,000	74,000	60,000	79,000	60,000	68,000	112,000	167,000	71,000	78,000	60,000	85,000	70,000	46,000	46,000	79,000	56,000	65,000	59,000	84,000	57,000	51,000	53,000	62,000	46,000	52,000	66,000	83,000	69,000	83,000	69,000	63,000	78,000	61,000	70,000	87,000	91,000	74,000	60,000
Proceeds from sale of property, plant and equipment
3,000	2,000	3,000	0	2,000	14,000	0	0	0	-	-	-	-	0	0	-1,000	30,000	0	0	0	0	-	-	-	-	0	0	0	53,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of privately-held securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	69,000	140,000	0	-	0	0	6,000	-	5,000	4,000	4,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of notes receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,000	-3,000	3,000	-	2,000	10,000	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sales of publicly traded and privately held equity securities and collections of notes receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	5,000	7,000	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments for acquisitions of businesses, net of cash acquired
0	0	3,619,000	442,000	321,000	480,000	550,000	409,000	9,000	168,000	0	392,000	0	-	-	-	-	-	-	-	-	-1,000	415,000	64,000	8,000	274,000	0	0	0	-	-	-	-	0	0	0	370,000	-	-	-	-	0	0	0	4,000
Proceeds from divestiture of certain businesses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	12,000	0	0	30,000	0	-	-	-	-	14,000	9,000	1,000	1,416,000	-	-	-	-	-	-	-	-
Proceeds from Collection of Notes Receivable
-23,000	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-132,000	6,000	34,000	1,000
Payments for investments and acquisitions of certain technologies
2,000	12,000	22,000	87,000	28,000	24,000	36,000	9,000	103,000	42,000	42,000	19,000	28,000	27,000	64,000	23,000	18,000	264,000	0	0	2,000	25,000	0	-10,000	11,000	31,000	6,000	0	7,000	4,000	17,000	1,000	0	1,000	0	1,000	9,000	1,000	1,000	0	4,000	-	-	-	-
Proceeds from sales of investments and collections of notes receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,000	0	50,000
Cash provided by (used for) investing activities
-76,000	-49,000	-3,962,000	-620,000	-410,000	-595,000	-662,000	-491,000	-173,000	-289,000	-102,000	-479,000	-140,000	-532,000	-205,000	-102,000	-48,000	-170,000	-1,719,000	-246,000	-51,000	-83,000	-473,000	-124,000	-65,000	-363,000	-73,000	-28,000	-11,000	-273,000	-53,000	-187,000	-66,000	-51,000	-59,000	-82,000	968,000	-251,000	-79,000	-64,000	-74,000	-60,000	-93,000	-123,000	-517,000
Financing activities:
Payment of contingent consideration and royalty rights previously established in purchase accounting
76,000	0	71,000	57,000	7,000	3,000	11,000	5,000	0	3,000	12,000	0	18,000	30,000	0	14,000	21,000	54,000	15,000	0	87,000	19,000	0	3,000	12,000	53,000	92,000	15,000	0	142,000	0	1,000	3,000	7,000	0	0	0	-	-	-	-	6,000	0	15,000	502,000
Payments on short-term borrowings
300,000	0	0	0	1,000,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from short-term borrowings, net of debt issuance costs
1,000,000	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in commercial paper
-714,000	-588,000	-662,000	305,000	370,000	424,000	-875,000	788,000	-316,000	-70,000	240,000	1,013,000	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on borrowings from credit facilities
479,000	0	0	0	0	-	-	-	-	0	0	1,481,000	735,000	240,000	290,000	0	40,000	0	170,000	395,000	0	0	160,000	365,000	285,000	100,000	0	0	240,000	120,000	0	140,000	120,000	140,000	175,000	0	250,000	0	0	0	200,000	-	-	-	-
Proceeds from borrowings on credit facilities
1,839,000	0	0	0	0	0	0	499,000	70,000	0	0	1,140,000	1,016,000	300,000	290,000	0	40,000	0	170,000	395,000	0	0	160,000	365,000	285,000	100,000	0	0	240,000	120,000	0	131,000	120,000	140,000	175,000	0	250,000	0	0	0	200,000	-	-	-	-
Payments on long-term borrowings and debt extinguishment costs
1,000,000	2,088,000	0	0	1,472,000	0	0	0	602,000	0	400,000	350,000	250,000	0	0	250,000	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	750,000	500,000	600,000	0	900,000	0	2,100,000	225,000	0	500,000
Proceeds from long-term borrowings, net of debt issuance costs
0	986,000	2,000,000	0	4,243,000	-2,000	0	-1,000	990,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments for acquisitions of treasury stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	125,000	225,000	75,000	100,000	100,000	100,000	250,000	112,000	138,000	-	-	-	-	-	-	-	-	-	-	-	-
Cash used to net share settle employee equity awards
57,000	1,000	3,000	1,000	60,000	2,000	2,000	2,000	50,000	1,000	2,000	1,000	61,000	5,000	1,000	-1,000	57,000	4,000	0	1,000	61,000	3,000	1,000	0	47,000	-54,000	1,000	1,000	24,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuances of shares of common stock
42,000	10,000	50,000	10,000	53,000	7,000	41,000	15,000	38,000	6,000	35,000	11,000	33,000	3,000	35,000	46,000	27,000	17,000	27,000	16,000	54,000	8,000	19,000	9,000	24,000	15,000	40,000	9,000	10,000	1,000	11,000	0	9,000	-1,000	13,000	0	9,000	3,000	14,000	0	14,000	1,000	19,000	1,000	12,000
Cash provided by (used for) financing activities
256,000	-724,000	1,314,000	256,000	2,127,000	425,000	151,000	726,000	130,000	-68,000	-139,000	332,000	-15,000	28,000	34,000	-217,000	-51,000	-237,000	761,000	846,000	-94,000	-14,000	18,000	6,000	-160,000	-265,000	-138,000	-107,000	-114,000	-262,000	-239,000	-131,000	-132,000	-308,000	-179,000	-750,000	-491,000	-609,000	14,000	73,000	14,000	-127,000	-206,000	1,000	-488,000
Effect of foreign exchange rates on cash
-9,000	12,000	-2,000	0	0	1,000	-4,000	-6,000	1,000	1,000	1,000	1,000	1,000	-3,000	1,000	-2,000	2,000	1,000	-3,000	1,000	-3,000	-2,000	-2,000	-1,000	1,000	-1,000	1,000	0	-1,000	1,000	1,000	-2,000	3,000	1,000	-6,000	1,000	2,000	0	4,000	-3,000	-1,000	-	-	-	-
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents
93,000	-69,000	-2,147,000	-73,000	2,067,000	-151,000	-14,000	-174,000	151,000	328,000	213,000	150,000	-161,000	169,000	-201,000	100,000	19,000	14,000	-553,000	661,000	-345,000	341,000	-111,000	166,000	-26,000	-354,000	41,000	262,000	61,000	-145,000	-19,000	87,000	17,000	-9,000	122,000	-441,000	382,000	-411,000	-187,000	292,000	-345,000	-517,000	187,000	297,000	-744,000
Adjustments to reconcile net income (loss) to cash provided by operating activities
Stock-based compensation expense
42,000	41,000	42,000	38,000	36,000	36,000	36,000	32,000	36,000	31,000	34,000	32,000	30,000	29,000	29,000	30,000	28,000	28,000	26,000	27,000	26,000	24,000	26,000	27,000	26,000	28,000	27,000	26,000	24,000	23,000	28,000	30,000	27,000	32,000	31,000	33,000	32,000	28,000	30,000	36,000	56,000	33,000	33,000	33,000	45,000
Fair value of contingent consideration recorded in purchase accounting
0	0	-4,000	44,000	87,000	58,000	50,000	140,000	0	-	-	-	-	-	-	-	-	-	-	-	-	3,000	-3,000	0	3,000	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-